Welcome to our dedicated page for Corvus Pharmaceu news (Ticker: CRVS), a resource for investors and traders seeking the latest updates and insights on Corvus Pharmaceu stock.
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) is a clinical-stage biopharmaceutical company based in South San Francisco, California that focuses on immunotherapy for cancer and immune diseases. Company news frequently highlights progress with its lead ITK inhibitor, soquelitinib, and other clinical-stage candidates in oncology and immunology.
Investors following CRVS news can expect updates on clinical trial milestones, including the registration Phase 3 trial of soquelitinib in relapsed/refractory peripheral T cell lymphoma (PTCL) and randomized trials in atopic dermatitis. Corvus regularly reports interim and final data from Phase 1 and Phase 1b/2 studies, such as results in T cell lymphomas and atopic dermatitis, as well as presentations at major medical meetings like the American Society of Hematology (ASH), the European Society for Medical Oncology (ESMO) and rheumatology congresses.
News releases also cover business updates and financial results, where the company discusses its development strategy for ITK inhibition across cancer and immune diseases, cash runway, and collaborations. Additional announcements may describe progress with ciforadenant in metastatic renal cell cancer, the partner-led mupadolimab program in non-small cell lung cancer, and the Autoimmune Lymphoproliferative Syndrome (ALPS) trial conducted with the National Institute of Allergy and Infectious Diseases.
This CRVS news page aggregates these disclosures so readers can review clinical data announcements, regulatory designations, collaboration updates and corporate events in one place. For those tracking immuno-oncology and immune disease pipelines, Corvus news provides insight into the evolution of its ITK platform and related investigational therapies.
Corvus Pharmaceuticals (NASDAQ: CRVS) announced it will host a conference call and webcast on November 12, 2024 at 4:30 pm ET to provide a business update and report third quarter 2024 financial results. The conference call can be accessed toll-free at 1-800-717-1738 (domestic) or 1-646-307-1865 (international). A live webcast will be available through the company's investor relations section, with a replay accessible for 90 days on Corvus' website.
Corvus Pharmaceuticals (NASDAQ: CRVS) has initiated a registrational Phase 3 clinical trial of soquelitinib for patients with relapsed/refractory peripheral T-cell lymphoma (PTCL). Soquelitinib, a potential first-in-class ITK inhibitor, has been granted Orphan Drug Designation and Fast Track Designation by the FDA. The trial will enroll approximately 150 patients across 40 sites in the US, Canada, Australia, and South Korea.
The randomized, controlled study will compare soquelitinib to standard chemotherapy, with a primary endpoint of progression-free survival. Soquelitinib's unique mechanism of action, based on selective ITK inhibition, shows potential for treating T cell lymphomas, solid tumors, and immune diseases. This trial marks a significant milestone for Corvus and PTCL patients, as there are currently no fully approved agents for relapsed PTCL treatment.
Corvus Pharmaceuticals (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference in New York from September 9-11, 2024. Richard A. Miller, M.D., president and CEO, and Jeffrey Arcara, chief business officer, will represent the company.
Key points:
- One-on-one meetings with investors scheduled
- Corporate overview presentation on September 10 at 12:00pm ET
- Live webcast available, accessible for 90 days post-event
- Webcast link provided in the investor relations section of Corvus website
This conference participation highlights Corvus Pharmaceuticals' efforts to engage with investors and showcase their latest developments in the biopharmaceutical industry.
Corvus Pharmaceuticals (CRVS) provided a Q2 2024 business update, highlighting progress in its soquelitinib (ITK inhibitor) program. Early results from the Phase 1 trial in atopic dermatitis showed clinical activity and cytokine changes consistent with ITK inhibition. The company is advancing toward initial enrollment in a Phase 3 trial for peripheral T cell lymphoma (PTCL) in Q3 2024. In the ongoing Phase 1/1b PTCL trial, soquelitinib demonstrated a 39% objective response rate, including 26% complete responses. Corvus reported $47.2 million in cash as of June 30, 2024, expecting to fund operations into Q4 2025. The company anticipates 2024 net cash used in operating activities between $24-$27 million.
Corvus Pharmaceuticals (Nasdaq: CRVS) has received FDA Fast Track Designation for soquelitinib, targeting adult patients with relapsed or refractory peripheral T cell lymphoma (PTCL) after at least two lines of systemic therapy. This designation underscores the significant unmet need in PTCL treatment, where current options offer efficacy and high toxicity. Corvus is on track to initiate patient enrollment in a registrational Phase 3 trial for PTCL in Q3 2024.
The Fast Track program aims to expedite development and review of drugs addressing serious conditions and unmet medical needs. Soquelitinib has also received FDA Orphan Drug Designation for T cell lymphoma treatment, providing benefits such as tax credits and seven years of post-approval marketing exclusivity.
Corvus Pharmaceuticals (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, has announced a conference call and webcast scheduled for August 6, 2024, at 4:30 pm ET (1:30 pm PT). The event will provide a business update and report second quarter 2024 financial results. Interested parties can access the call by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international), or by using a provided link for instant telephone access. A live webcast will be available through the investor relations section of Corvus' website, with a replay accessible for 90 days post-event.
Corvus Pharmaceuticals (NASDAQ: CRVS) announced the publication of preclinical data in Science Signaling, demonstrating the potential of ITK inhibition with soquelitinib for treating inflammatory diseases. The study, conducted by Cornell University researchers, showed that ITK inhibition induces switching of proinflammatory Th17 cells into anti-inflammatory Treg cells, both in vitro and in vivo.
Key findings include:
- Dose-dependent inhibition of Th17 cell differentiation and increase in Foxp3+ Treg cells
- Switched Foxp3+ Treg cells suppress naïve T cell proliferation
- Significant reduction of Th17 cells in the lung in a mouse model of allergic airway inflammation
This research supports Corvus' view on the broad potential of ITK inhibition for treating autoimmune, allergic, and inflammatory diseases.
Corvus Pharmaceuticals, a clinical-stage biopharmaceutical company listed on NASDAQ under the ticker CRVS, has announced that it will participate in the Jefferies Global Health Conference in New York from June 5-7, 2024. The company's CEO, Richard A. Miller, and Chief Business Officer, Jeffrey Arcara, will present a corporate overview and conduct one-on-one meetings with investors. The presentation is scheduled for June 5 at 3:00 pm ET and will be webcast live, with the recording available for 90 days on the company's investor relations webpage.
Corvus Pharmaceuticals, a clinical-stage biopharmaceutical company, reported strong progress in advancing soquelitinib for PTCL and generating early data for atopic dermatitis. Recent financing provided runway for expected clinical readouts in 2024-2025. Positive Phase 1 trial results for ciforadenant in renal cell cancer. Corvus also collaborates with Kidney Cancer Research Consortium and Angel Pharmaceuticals. Financially, Corvus reported cash, cash equivalents, and marketable securities of $22.1 million as of March 31, 2024, with expected full year 2024 net cash used in operating activities between $24-27 million.
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) will provide a business update and report first quarter 2024 financial results on May 6, 2024. The company will host a conference call and webcast at 4:30 pm ET / 1:30 pm PT. Investors can access the call through dial-in numbers or the webcast link. A replay will be available on the company's website.